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ABSTRACT 
INTRODUCTION: The last three decades have seen several major advances in the 
multidisciplinary management of locally advanced rectal cancer (LARC). Although rectal cancer 
management varies globally, the standard of care for clinical stage II/III rectal cancer in North 
America remains chemoradiation followed by total mesorectal excision and adjuvant therapy.  
EVIDENCE ACQUISITION: In this review we evaluate the evidence for neoadjuvant therapy in 
LARC and the variety of treatment options available.   
EVIDENCE SYNTHESIS: We identify heterogeneity of outcomes in stage II/III rectal cancer, 
leading to the potential for overtreatment. The PROSPECT trial is a multi-centre, international 
effort  to determine whether a selective approach to provision of radiotherapy in stage II/ III 
LARC is a viable treatment option. Unlike many other studies, the aim of PROSPECT is to 
reduce treatment rather than increase the intensity of preoperative therapy. 
CONCLUSION: LARC is a heterogeneous disease with varying risk of relapse. Studies are 
underway to attempt to individualise care to avoid overtreatment while maintaining excellent 
oncologic outcomes.   
 
Key words: locally advanced rectal cancer, stage II/III rectal cancer, neoadjuvant therapy, 
radiotherapy, individualised treatment
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Introduction 
The clinical management of locally advanced rectal cancer (LARC) has become increasingly 
complex over the past three decades, now requiring multi-disciplinary specialist input from the 
time of diagnosis to correctly allocate multi-modality treatment. Rectal cancer is distinct from 
colon cancer, carrying an increased risk of local and regional recurrence resulting from its 
anatomic location within the narrow confines of the bony pelvis, which makes margin-negative 
surgical resection difficult. This local recurrence risk has driven major advances in colorectal 
surgical oncology, including refinements in pre-and post-treatment imaging, improvements in 
surgical technique and new neoadjuvant therapies. As treatments evolve and knowledge of the 
disease process builds, rectal cancer management is becoming increasingly personalized, taking 
into consideration the patient’s own informed preferences. The aim of the present review is to 
provide an overview of modern neoadjuvant therapy for locally advanced rectal cancer and to 
discuss the rationale behind the selective use of radiotherapy for some patients.  
 
Modern management of LARC with long-course chemoradiation 
The current standard for management of LARC in North America includes chemoradiation 
(chemoRT), total mesorectal excision, and adjuvant systemic chemotherapy 1. Such a strategy 
aims to achieve a margin-negative resection whilst managing the dual risk of local and systemic 
recurrence after surgery. This modern standard is built on the results of the landmark National 
Surgical Adjuvant Breast and Bowel Project (NSABP) R01 study, published over 30 years ago, 
which demonstrated that pelvic irradiation led to an impressive reduction in local recurrence 
rates, from 25% to 16% 
2
. Since then several landmark trials have gone on to shape modern 
oncological practice. The German Rectal Cancer Study Group 
3
 demonstrated the advantage of 
pre-operative over post-operative pelvic radiotherapy: a marked reduction in both acute and 
long-term treatment-related toxicity (Grade 3/4 toxicity 27% vs. 40% and 14% vs. 24%, 
respectively). Subsequently, the EORTC Radiotherapy Group Trial 22921 reported that with the 
addition of pre-operative fluorouracil-based chemotherapy, local recurrence (LR) rates fell 
further to below 10% 
4
. The FFCD 9203 trial provided further evidence of the benefits of 
chemoradiation for cT3/4 rectal cancers, demonstrating that in comparison to radiotherapy alone, 
chemoRT halved the rates of LR at 5 years (8.1% vs. 16.5%) 5. That trial also found higher rates 
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 of pathologic complete response (pCR) (11.4% vs. 3.6%) with chemoRT, and only a modest 
increase in treatment-related toxicity (Grade 3/4 toxicity 15% vs. 3%).  
Subsequent attempts to refine chemoRT regimens in the intervening years have proven less 
successful. For example, the addition of oxaliplatin (a drug with proven efficacy in the metastatic 
and adjuvant settings for colorectal cancer) to neoadjuvant therapy has not yielded impressive 
results. Six phase III trials (STAR-01, ACCORD-12, NSABP R-04, CAO/ARO/AIO-04, 
PETACC-A6, and FOWARC) have evaluated oxaliplatin combination chemoRT to date 
6-10
; 
only 2 have reported potential benefit for the addition of oxaliplatin. The German 
CAO/ARO/AIO-04 trial reported a statistically significant improvement in disease-free survival 
(75.9% vs. 71.2%) and pCR (17% vs. 13%) with oxaliplatin added to chemoRT; however, its 
results are potentially confounded by variations in fluorouracil scheduling between treatment 
arms 
8
. The Chinese FOWARC trial reported that FOLFOX-RT was associated with higher pCR 
rates and increased down-staging compared with 5FU-based chemoRT 
10
. Such findings were 
not reproduced in the four other trials. However, the addition of oxaliplatin was associated with 
significantly higher rates of Grade 3/4 treatment-related toxicity in 4 of the 6 trials; 
consequently, 5FU-based chemoRT remains the recommended long-course regimen for LARC 
according to the NCCN guidelines 
11
.  
No novel radiotherapy combinations for LARC have been demonstrated superior to current 
neoadjuvant treatments. For example, the addition of targeted therapies including anti-vascular 
endothelial growth factor (anti-VEGF) and anti-endothelial growth factor receptor (anti-EGFR) 
agents to long-course chemoRT regimens has been evaluated in phase II trials, but these failed to 
meet primary endpoints 
12-14
. 
 
Short-course radiation for cT3/4 LARC 
The use of short-course radiation (SCRT) with immediate surgery for cT3/4 LARC is advocated 
by many oncologists, predominantly from European countries. Short-course radiation involves 
25 Gy given over 5 fractions and is considerably less expensive and associated with lower early 
radiation-related toxicity compared with long-course chemoRT (LCRT) 15. However, performing 
surgery early reduces the potential for significant tumour down-staging and also for complete 
response to treatment.  
The Polish and TransTasman trials compared SCRT with LCRT 15, 16. Though the Polish 
Colorectal Study Group trial 
15
 was powered to detect a difference of at least 15% in rates of 
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 sphincter preservation, it failed to meet this endpoint, finding permanent colostomy rates of 
56.9% in the SCRT group and 51.6% in the LCRT group in 312 patients. The authors concluded 
that because survival, distant and local recurrence did not differ between the groups, SCRT was a 
reasonable alternative to LCRT. However, SCRT was associated with a higher involved 
circumferential resection margin rate than LCRT (12.9% vs. 4.4%). As expected given that 
surgery was performed immediately, the pCR rate in the SCRT group was 1% compared with 
16% in the LCRT group, demonstrating the down-staging benefits of LCRT.  
The Trans-Tasman Radiation Oncology Group trial found no statistically significant differences 
in overall survival, local or distant recurrence-free survival between SCRT and LCRT (n=163 
per group), but did report a trend towards increased LR with SCRT (7.5% vs. 4.4%) 
16
. This 
trend may be confounded by the higher proportion of low rectal cancers in the SCRT group (30% 
vs. 19%), which have a greater risk of LR compared with mid-upper rectal tumours. Similar to 
the Polish trial, pCR rates were greater with LCRT (15% vs. 1%), but circumferential margin 
positivity was comparable (4% vs. 5%). The authors concluded that despite the lack of 
differences in survival and recurrence, LCRT may be more effective in reducing LR for distal 
tumours.  
SCRT with delayed surgery to some degree overcomes the drawback of SCRT with immediate 
surgery, as down-staging responses have been demonstrated. After initial non-randomized 
studies reported more down-staging and pCR in comparison to SCRT with early surgery 
17, 18
, 
Stockholm III compared SCRT with immediate surgery, SCRT with delayed surgery, and LCRT 
in a randomized trial of 840 patients with resectable rectal cancer 19, 20. In comparison to SCRT 
with immediate surgery, SCRT with delayed surgery was associated with fewer post-operative 
complications and higher rates of tumour down-staging, tumour regression and pCR (11.8% vs. 
1.7%). The authors concluded that SCRT with delayed surgery was a viable alternative to 
conventional SCRT. Unfortunately, the trial was limited by a prolonged recruitment period 
(1998-2013), during which time modifications in rectal management and clinical staging are 
recognized to have improved outcomes. For example, the LR rate decreased on a population 
basis from 15% to 5% during the period studied. The introduction of MRI staging in 2003 also 
influenced patient recruitment by enabling selection of patients with locally advanced tumours in 
later years.    
These trials have not settled the debate regarding which radiation modality should be used 
routinely in LARC, but they do highlight the importance of considering local staging 
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 characteristics and tumour location when selecting the appropriate therapy. Given the wide 
spectrum of disease, it may be possible to define groupings of cT3/4 tumours by risk of LR, 
determining the optimal neoadjuvant strategy. A Northern European strategy developed in the 
2000s advised distinct treatments for LARC patients in ‘favourable’, ‘intermediate’, or advanced 
risk categories, also referred to as ‘The Good, the Bad and the Ugly’ by Blomqvist and Gilmius 
21. Patients with cT3a-b tumours were considered to have low risk of LR and could proceed 
straight to surgery. The proposed appropriate treatment for those with cT3c or cN+ or low rectal 
tumours without mesorectal fascial involvement, at intermediate risk, was SCRT followed by 
surgery, and for patients with cT4 or mesorectal fascial involvement, considered advanced, 
LCRT or in certain cases SCRT and delayed surgery.   
 
Systemic chemotherapy prior to chemoRT and surgery for LARC 
Though neoadjuvant therapy in rectal cancer conventionally consists of pelvic irradiation, 
interest is growing in the use of systemic chemotherapy prior to surgery. Several trials and 
single-centre studies have tested the benefit of systemic chemotherapy with 5-FU/ capecitabine 
and oxaliplatin-based regimens (currently recommended postoperatively) 11, 22-27. The key 
benefit of administering adjuvant chemotherapy prior to surgery is the potential to reduce the risk 
of distant recurrence, which is now substantially more common than LR, by targeting 
micrometastases at the outset. Preoperative chemotherapy also enables in vivo assessment of 
chemosensitivity by the degree of tumour regression or down-staging. Finally, tolerance for 
chemotherapy may be limited in patients recovering from major cancer surgery, sometimes 
preventing a complete course of treatment. Up to 27% of patients never start adjuvant 
chemotherapy after rectal resection 
28
 and 50% don’t receive the full dose 
29
, in many cases as a 
consequence of prolonged recovery. Giving chemotherapy prior to surgery eliminates the need to 
defer closure of diverting ileostomies, allowing earlier restoration of gastrointestinal continuity. 
Preoperative systemic chemotherapy can also induce local tumour regression, which may enable 
more patients to avoid radiotherapy.    
Several institutional series and phase II trials have evaluated the oncological efficacy of 
induction or consolidation chemotherapy (ICT or CCT) delivered before or after 
chemoRT in LARC 
12, 14, 22, 23, 25, 30
. To date, the literature on this topic is in part limited by a lack 
of phase III data and adequate control groupings within the studies. Comparisons between North 
American and European studies are also limited by heterogeneous inclusion criteria, as some 
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 European studies evaluated only high-risk LARC. In general, despite improved compliance and 
toxicity data, data on response rates are variable; pCR rates range from 14-36% for ICT/ 
chemoRT based regimens 
12, 22, 25
. Despite these limitations, we review the available data in 
detail in this section. 
Several studies suggest that a short 2-cycle course, rather than the standard 4 cycles, of 
chemotherapy may be sufficient for induction prior to chemoRT. A small phase II study, 
including 57 LARC patients with cT2-4/ N+ tumours randomized to 2 cycles of ICT with 
mFOLFOX6 prior to chemoRT or chemoRT alone, found comparable response between the 2 
treatment arms, and a 28% pCR in the ICT/chemoRT group 
31
. Two institutional series with 
similar inclusion criteria from Spain and Denmark reported pCR rates of 29% in 52 patients 
(following 2 cycles of FOLFOX prior to chemoRT) and 23% in 88 patients (after 2 cycles of 
CapOx prior to chemoRT), respectively 
24, 32
.   
A pooled analysis of data from 269 patients from 2 European phase II trials suggests that 
chemotherapy followed by chemoRT may be especially beneficial for patients with high-risk 
LARC, defined as tumour <1 mm from the mesorectal fascia, cT3c/d or T4 tumours, and low 
tumours involving pelvic floor musculature. The pCR rate was 20.0% among the 240 patients in 
the EXPERT and EXPERT-C trials who underwent surgery, and T stage and N stage down-
staging was observed in 56.6% and 43.4%, respectively 33. Although both trials lacked a 
chemoRT-alone control group, these results were thought to represent improvements in treatment 
response with good long-term disease control in a high-risk population. Furthermore, compliance 
with treatment was good and toxicity was minimal 14, 22. 
The Spanish GCR-3 phase II randomized trial found that the key benefit of ICT is improved 
delivery of treatment, due to better toxicity profiles 
30
. GCR-3 compared short- and long-term 
outcomes between 49 high-risk LARC patients treated with chemoRT and then surgery (71% of 
whom received postoperative adjuvant chemotherapy_ with those of 54 patients treated with ICT 
(CAPOX) followed by chemoRT. Grade 3/4 toxicity was reported in 19% of patients in the ICT 
arm compared with 54% in the postoperative chemotherapy arm. The study found no difference 
in pCR rates (13 vs. 14%) or 5-year local (2 vs. 5%) or distant (21 vs. 23%) recurrence rates 
between the groups. The trial defined high risk LARC as tumours within 12 cm of the anal verge 
with the following features: extending to within 2 mm of the mesorectal fascia, cT3 tumours in 
the lower third of the rectum, cT4 disease, and/or cN+ disease. The fact that the ICT group 
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 contained a higher number of T4 tumours (13% vs. 6%) and low T3 tumours (32% vs. 23%) than 
the chemoRT group may have limited power in detecting differences in response.   
The AVACROSS study 
12
 found a much higher pCR rate (36%) for ICT with XELOX and 
bevacizumab, evaluated in 45 patients with high-risk LARC, defined similarly to the GCR-3 
study. However, 2 of the 47 enrolled patients died during neoadjuvant treatment, and there were 
higher-than-average rates of surgery-related complications (including anastomotic leaks in 5 of 
47 patients and need for re-operation in 11 of 47 (24%)) after treatment with the bevacizumab-
based regimen.  
Memorial Sloan Kettering reported that in a small cohort of patients with LARC treated with 
ICT followed by chemoRT, the addition of FOLOX was associated with a substantial increase in 
tumour down-staging and a 36% pCR rate 26. A recent follow-up study found that ICT was 
associated with higher received doses of 5-FU and oxaliplatin and more patients completing the 
planned regimen compared with standard preoperative chemoRT with planned postoperative 
adjuvant chemotherapy 
27
. Specifically, 78% of the 308 patients receiving ICT completed 8 
cycles including oxaliplatin chemotherapy compared to 41% of the 320 who had post-operative 
therapy. The complete response rate with the addition of ICT was 36% compared with 21% 
treated with preoperative chemoRT alone.   
The timing trial published by Garcia-Aguilar and colleagues in 2016 demonstrated good 
tolerance of systemic chemotherapy delivered after chemoRT and prior to surgery 
34
. More 
cycles of FOLFOX were associated with greater rates of tumour regression and pCR. It is not 
possible to determine to what extent the increased time delay to surgery from completion of 
radiation contributed to these impressive responses (up to 38% with 6 cycles of FOLFOX), but 
these results add to the evidence that preoperative chemotherapy may lead to significant tumour 
down-staging. 
 
Heterogeneity in outcomes and LR within LARC—one size does not fit all 
We have now reached an era in which trials of neoadjuvant regimens consistently report very 
low LR rates, now in single digit percentages. Consequently, LR risk will rarely be a primary 
endpoint in future trials due to the large number of patients required to detect significant 
differences in LR rates. Rectal cancer management has also advanced in many other ways, most 
notably through the widespread adoption of total mesorectal excision (TME) and increasing 
specialisation in colorectal surgery over the past 30 years. TME consists of precise anatomical 
Page 9 of 20 
Minerva Chirurgica
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
66 
67 
68 
69 
70 
81 
82 
83 
84 
85 
86 
87 
88 
89 
90 
91 
92 
93 
94 
95 
 excision of the rectum within its enveloping mesorectum by dissecting sharply between the 
visceral and parietal layers of the endopelvic fascia. This procedure ensures complete removal of 
all draining loco-regional lymph nodes, achieving higher rates of clear circumferential resection 
margins, minimising blood loss and injury to autonomic pelvic nerves. TME has not been 
formally tested in randomised clinical trials, but is widely considered to have been a major 
contributor to improved local recurrence rates 35-37. The widespread adoption of the technique 
has also driven improvements in surgical training and rectal cancer surgical specialisation 
38
, 
further contributing to improved oncological outcomes.    
Evidence is increasing that TME alone is sufficient to treat tumours considered to have good 
prognosis based on MRI staging. Low LR rates (1.7%) were reported by the Mercury study 
group in a prospective non-randomised observational study in which 122 patients with cT3a-b 
tumours (regardless of clinical N stage) were treated by TME without neoadjuvant therapy 
39
. 
However, the distant recurrence rate in this cohort was 19%.  
Another study supporting individualised treatment was the Dutch rectal cancer trial, published in 
2001 
40
. One of the first studies examining the influence of preoperative pelvic radiation on LR 
in the era of improved surgical quality via total mesorectal excision, the trial demonstrated that 
SCRT was associated with significantly fewer recurrences than surgery alone. The long-term 
results also showed that SCRT appeared to be more beneficial for patients with lower-lying 
tumours, tumours with clinical nodal involvement, or tumours not encroaching on the surgical 
circumferential resection margin 
41
. Of note, despite a well-defined operative technique, patients 
who had poorer quality resection specimens had worse long-term survival 42. Other results 
confirm the critical importance of surgical technique is in rectal cancer management 
43
.  
Criticism is mounting of the definition of LARC as clinical stage II and III, as this group of 
tumours is heterogeneous and current staging fails to adequately account for local spread. 
Several studies indicate that LR risk can be stratified based on T and N staging. In 2002, 
Gunderson and colleagues analysed the outcomes of 2551 patients from 3 North American rectal 
cancer trials to generate the following categories of LR risk: low, T1/2N0; intermediate, T1/2N1 
and T3N0; moderately high, T1/2N2, T3N1, andT4N0; and high, T3N2 and T4N1/2 44. LR rates 
were lower in the intermediate risk group (6-8%) compared with the moderately high (8-15%) 
and high-risk (15-22%) groups. Similarly, the highest T and N stages were associated with 
greater risk of distant metastases (T3N2 45% and T4N2 50%). These data further indicate that 
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 pelvic irradiation may not be required for patients with T1/2N1 or T3N0 stage cancer as long as 
high quality TME with clear margins is performed.  
Later studies supported these correlations between T/N staging and LR risk and revealed their 
relationship to individualisation of treatment. In 2002, the Intergroup 0114 trial of adjuvant 
therapy in rectal cancer reported LR rates of 9% among patients with T1/2N+ or T3N0 tumours 
and 18% among those with T3N+ or T4 45. An analysis by Gundersson and colleagues in 2004 46 
of 5 phase III North American trials including 3791 patients reported that in patients with 
T1/2N1 or T3N0 rectal cancer, the addition of radiation to combined modality treatment did not 
appear to improve long term disease-specific or overall survival. Together, these results 
demonstrate that the heterogeneity of outcomes in stage II and stage III rectal cancer calls for 
individualisation of treatment. For patients with locally advanced rectal cancer, one size does not 
fit all.  
 
Disadvantages of pelvic radiotherapy and potential for overtreatment  
Pelvic irradiation remains the current standard for cT3/4/ N+ locally advanced rectal cancer in 
many countries, but in patients considered to have low risk of loco-regional relapse, the risk of 
overtreatment must be considered given the toxicity of radiotherapy. Short-term toxicities are 
common, and often affect the patient’s ability to complete treatment. These include pelvic 
fibrosis, which can make surgical resection more challenging, and autonomic nerve injury, which 
can cause sexual, bladder and bowel dysfunction. Quality of life is reported to be lower in 
patients treated with radiotherapy compared with those who do not 41; up to 50% of patients who 
have chemoRT followed by TME report incontinence of stool, faecal urgency and having to 
wear a pad 
47, 48
. Other risks of radiation to the pelvis include small bowel injury with associated 
long-term enteritis, and depletion of pelvic bone marrow, which can limit tolerance for cytotoxic 
chemotherapy. As rates of LR after combined modality treatment and TME for rectal cancer are 
now very low, the challenge ahead lies in addressing the balance of oncologic success with the 
risk of long-term sequelae and impaired quality of life. 
 
The Preoperative Radiation or Selective Preoperative Radiation and Evaluation before 
Chemotherapy Trial (PROSPECT) 
The PROSPECT trial (NCCTG-N1048; PROSPECT stands for Preoperative Radiation or 
Selective Preoperative Radiation and Evaluation before Chemotherapy and TME) is a large, 
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 multicentre phase II/III trial which compares whether standard chemoRT can be replaced in 
selected patients with neoadjuvant FOLFOX (Figure 1). The rationale for the trial is the recent 
results (discussed above) indicating that not all patients require RT, particularly if LR risk is low. 
In addition, systemic chemotherapy prior to surgery is well tolerated and appears to induce 
down-staging responses whilst potentially mitigating systemic relapse risk.  
In PROSPECT, patients with intermediate-risk LARC (T1/2N1, T3N0, T3N1) without 
involvement of the circumferential resection margin and who are candidates for sphincter-
preserving surgery are randomly assigned to 2 groups: ‘standard’ or ‘selective’ management. In 
the standard arm, patients receive preoperative chemoRT (5FU- or capecitabine-based LCRT 
followed by TME and then adjuvant FOLFOX chemotherapy for 8 cycles). In the selective arm, 
patients receive 6 cycles of FOLFOX prior to being restaged; those with > 20% clinical response 
proceed to surgical resection followed by 6 cycles of adjuvant FOLFOX, while those with < 20% 
response are recommended to be treated with conventional chemoRT followed by surgery and 2 
cycles of adjuvant FOLFOX. In the selective arm, patients who do not receive pre-operative 
chemoRT and have a disease-positive circumferential surgical resection margin are also given 
post-operative chemoRT. The trial will determine whether the selective approach is a reasonable 
alternative to conventional chemoRT; that is, whether it leads to similar short-term surgical and 
long-term oncological outcomes (local and distant recurrence).  
The phase II single-centre pilot study recruited 32 patients who were candidates for sphincter-
preserving surgery 
49
. On clinical staging 23 (72%) had stage III (cN+) tumours, 29 (91%) were 
cT3, and 3 tumours were cT2N+. Of the 30 patients who completed 6 cycles of FOLFOX-based 
preoperative chemotherapy, all 30 demonstrated tumour regression and 8 had complete 
responses. All patients underwent R0 resections and no local recurrences were detected at a 
median of 54 months follow-up; 4 patients developed distant metastatic recurrence. Only 2 
patients did not complete the treatment plan due to chemotherapy-related cardiac toxicity. These 
results suggest that omission of radiotherapy may be acceptable in a subset of patients with 
LARC, providing preliminary data supporting the full phase II PROSPECT trial. At the present 
time, the trial has moved from phase II to phase III and is near its target accrual of 1140 patients.   
 
Summary 
In summary, the past 3 decades have seen an evolution in the management of locally advanced 
rectal cancer. Preoperative imaging has been optimised, surgical techniques have improved, and 
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 multimodality therapy has been applied widely, and as a consequence local recurrence is no 
longer common. As we progress in the 21
st
 century, mitigation of systemic relapse risk is now 
the principal challenge, whilst limiting toxicity from potential overtreatment. Individualisation of 
therapies will become increasingly commonplace, based on baseline imaging assessments and 
patient choice. The PROSPECT trial, which is close to completion, will determine whether RT 
may be selectively administered in stage II/ III LARC based on response to induction 
chemotherapy, which would limit treatment-related toxicity by avoiding overtreatment.    
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 Figure 1. Design of the PROSPECT randomized multi-centre phase II/III trial (NCCTG-
N1048).Pre-operative Radiation or Selective Preoperative Radiation and Evaluation before 
Chemotherapy and TME compares neoadjuvant FOLFOX with selective use of chemoRT in 
LARC. CMT, 5-FU/capecitabine + RT; Cap, capecitabine; LAR, low anterior resection; TME, 
total mesorectal excision. 
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